Breast Cancer Estrogen receptor Clinical Subtype Mutation

Cell line status

MCF7 Positive Hormone PIK3CA E545K
receptor +
T47D Positive Hormone PIK3CA
receptor + H1047R
BT483 Positive Hormone PIK3CA E542K
receptor +
ZR751 Positive Hormone PTEN
receptor +
ZR75b Positive Hormone PTEN
receptor +
ZR7530 Positive Hormone
receptor +
MDAMB134v Positive Hormone
1 receptor +
MDAMB415 Positive Hormone PTEN
receptor +
CAMA1 Positive Hormone PTEN
receptor +
LY2 Positive Hormone PIK3CA E545K
receptor +
600MPE Positive Hormone
receptor +
HCC70 Positive Hormone PTEN
receptor +
BT474 Positive HER2-positive PIK3CA K111N

HCC1569 Negative HER2-positive

MDAMB361 Positive HER2-positive PIK3CA E545K

MDAMB453 Negative HER2-positive PIK3CA

H1047R
SKBR3 Negative HER2-positive
AU565 Negative HER2-positive
SUM225 Negative HER2-positive
HCC202 Negative HER2-positive PIK3CA E545K

UACC812 Positive HER2-positive PIK3CA N345K

UACC893 Positive HER2-positive PIK3CA

H1047R
MDAMB468 Negative Triple negative PTEN
HBL100 Negative Triple negative
HCC38 Negative Triple negative
HCC1187 Negative Triple negative
HCC1954 Negative Triple negative PIK3CA
H1047R
HCC2185 Negative Triple negative PIK3CA E545K

MDAMB231 Negative Triple negative

BT20 Negative Triple negative PIK3CA
H1047R/P539R
BT549 Negative Triple negative PTEN
MDAMB157 Negative Triple negative PTEN
HS578T Negative Triple negative
HCC1500 Negative Triple negative
HCC3153 Negative Triple negative
MCF10A Negative Triple negative
MCF10F Negative Triple negative
MCF12A Negative Triple negative
SUM149PT Negative Triple negative
SUM159PT Triple negative PIK3CA H1047L

SUM185PE Negative Triple negative PIK3CA

H1047R
 All Tumors PIK3CA Wild Type PIK3CA Mutation
N Percent N Percent N Percent P-Value
N 157 101 56
Histology
Other 35 22.3 27 26.7 8 14.3
Ductal 122 77.7 74 73.3 48 85.7 0.108
Pathologic T
T1 57 36.3 40 39.6 17 30.4
T2 75 47.8 43 42.6 32 57.1
T3/4 25 15.9 18 17.8 7 12.5 0.3
Pathologic N
N0 101 65 71 72.3 30 53.6
N1-N3 56 35 30 27.7 26 46.4 0.039
ER
Negative 3 1.9 3 3 0 0
Positive 154 98.1 98 97 56 100 0.307
PR
Negative 32 20.4 16 15.8 16 28.6
Positive 125 79.6 85 84.2 40 71.4 0.066
Summary stage
I 45 28.8 34 34 11 19.6
II 90 57.7 51 51 39 69.6
III 21 13.5 15 15 6 10.7 0.067
Nuclear Grade
I 41 41.4 27 35.1 14 43.8
II 48 48.5 35 58.4 13 40.6
III 10 10.1 5 6.5 5 15.6 0.828

ER estrogen receptor
PR progesterone receptor
 3 Year 4 Year
Overall survival: N N Events Estimate 95% C.I. Estimate 95% C.I.
All 157 40 89.60% (84.5%, 94.8%) 86% 80.2%, 92.1%)
PIK3CA
Wild Type 101 26 88.50% (81.8%, 95.3%) 84.40% (76.6%, 92.3%)
Mutation 56 14 91.70% (83.9%, 99.5%) 89.40% 80.5%, 98.2%)
PIK3CA
Wild Type 101 26 88.50% (81.8%, 95.3%) 84.40% (76.6%, 92.3%)
Catalytic 35 9 90.00% (79.3%, 100%) 86.30% (73.7%, 98.8%)
Other 21 5 94.40% (83.9%, 100.0%) 94.40% (83.9%, 100.0%)
Recurrence-free survival:
All 157 36 91.20% (86.4%, 96%) 90.20% (85.2%, 95.3%)
PIK3CA
Wild Type 101 22 91.00% (85%, 97%) 89.60% (83%, 96.1%)
Mutation 56 14 91.40% (83.4%, 99.5%) 91.40% (83.4%, 99.5%)
PIK3CA
Wild Type 101 22 91.00% (85%, 97%) 89.60% (83%, 96.1%)
Catalytic 35 9 86.60% (74.4%, 98.9%) 86.60% (74.4%, 98.9%)
Other 21 5 100.00% 100.00%

N-number
C.I.-confidence interval
 5 Year
Estimate 95% C.I P-Value
84.40% (78%, 90.7%)

83.00% (74.8%, 91.2%)

86.90% (77%, 96.7%) 0.597

83.00% (74.8%, 91.2%)

82.10% (67.8%, 96.5%)
94.40% (83.9%, 100.0%) 0.773

87.40% 81.5%, 93.3%)

88.10% (81%, 95.1%)

86.20% (75.8%, 96.5%) 0.919

88.10% (81%, 95.1%)

86.60% (74.4%, 98.9%)
86.70% (69.5%, 100%) 0.799